Jefferies Group LLC Analysts Give Pfizer, Inc. (PFE) a $35.00 Price Target
Jefferies Group LLC set a $35.00 price target on Pfizer, Inc. (NYSE:PFE) in a research report report published on Thursday. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on PFE. Citigroup Inc. cut Pfizer from a neutral rating to a sell rating and lowered their target price for the company from $38.00 to $31.00 in a research note on Tuesday, May 16th. Credit Suisse Group cut Pfizer from an outperform rating to a neutral rating and lowered their target price for the company from $38.00 to $36.00 in a research note on Thursday, July 20th. Zacks Investment Research raised Pfizer from a sell rating to a hold rating in a research note on Friday, July 14th. Barclays PLC reissued a buy rating and issued a $38.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Finally, Sanford C. Bernstein reissued a buy rating and issued a $37.00 target price on shares of Pfizer in a research note on Wednesday, May 3rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $37.61.
Shares of Pfizer (PFE) opened at 33.39 on Thursday. The firm has a market cap of $198.58 billion, a P/E ratio of 24.43 and a beta of 1.00. Pfizer has a 12-month low of $29.83 and a 12-month high of $35.18. The firm has a 50-day moving average price of $33.25 and a 200-day moving average price of $33.42.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period last year, the firm posted $0.64 EPS. The business’s revenue was down 1.9% on a year-over-year basis. On average, equities research analysts expect that Pfizer will post $2.56 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/28/jefferies-group-llc-analysts-give-pfizer-inc-pfe-a-35-00-price-target.html.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.83%. Pfizer’s dividend payout ratio is presently 94.12%.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the transaction, the insider now directly owns 74,506 shares in the company, valued at $2,436,346.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,014 shares of company stock worth $4,062,493. Corporate insiders own 0.06% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Farmers National Bank raised its position in Pfizer by 3.2% in the second quarter. Farmers National Bank now owns 107,106 shares of the biopharmaceutical company’s stock valued at $3,598,000 after buying an additional 3,352 shares in the last quarter. RNC Capital Management LLC raised its position in Pfizer by 3.7% in the second quarter. RNC Capital Management LLC now owns 1,080,976 shares of the biopharmaceutical company’s stock valued at $36,310,000 after buying an additional 38,619 shares in the last quarter. Sentry Investment Management LLC raised its position in Pfizer by 1.0% in the second quarter. Sentry Investment Management LLC now owns 478,557 shares of the biopharmaceutical company’s stock valued at $16,075,000 after buying an additional 4,775 shares in the last quarter. Atlantic Trust LLC raised its position in Pfizer by 19.8% in the second quarter. Atlantic Trust LLC now owns 27,400 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 4,530 shares in the last quarter. Finally, WFG Advisors LP raised its position in Pfizer by 14.5% in the second quarter. WFG Advisors LP now owns 55,528 shares of the biopharmaceutical company’s stock valued at $1,865,000 after buying an additional 7,024 shares in the last quarter. Hedge funds and other institutional investors own 69.09% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.